Scarica l'app Stockscreener
1.98
13.35%
-0.305
Dopo l'orario di chiusura:
2.01
0.03
+1.52%
Precedente Chiudi:
$2.285
Aprire:
$2.21
Volume 24 ore:
1.77M
Relative Volume:
1.74
Capitalizzazione di mercato:
$231.31M
Reddito:
-
Utile/perdita netta:
$-26.33M
Rapporto P/E:
-7.0113
EPS:
-0.2824
Flusso di cassa netto:
$-17.65M
1 W Prestazione:
-8.33%
1M Prestazione:
+34.69%
6M Prestazione:
+86.79%
1 anno Prestazione:
+81.65%
Intervallo 1D:
$1.975
$2.24
Intervallo di 1 settimana:
$1.975
$2.34
Portata 52W:
$0.88
$2.34
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.98 | 266.94M | 0 | -26.33M | -17.65M | -0.2824 |
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 58.15B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.35 | 42.94B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.59B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.86 | 30.29B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
503.86 | 21.74B | 3.17B | 1.29B | 1.01B | 27.09 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-26 | Iniziato | ROTH MKM | Buy |
| 2024-04-22 | Iniziato | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Borsa (CRDL) Ultime notizie
Cardiol Therapeutics files $150 million shelf prospectus By Investing.com - Investing.com India
Cardiol Therapeutics files US$150M base shelf prospectus - TradingView
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission - PR Newswire
Cardiol Therapeutics (NASDAQ: CRDL) lines up new shelf to fund drug trials - Stock Titan
Cardiol Therapeutics Files For Mixed Shelf Offering Of Up To $150 Mln - TradingView
Cardiol Therapeutics Inc. Class A (TSX:CRDL) Gains Momentum as Cardiovascular Drug Pipeline Progress Strengthens Investor Optimism - kalkine.ca
Cardiol Therapeutics (TSX:CRDL) Healthcare Stock Latest Update - Kalkine Media
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Heart-drug developer Cardiol Therapeutics (CRDL) heads to a major New York investor conference - Stock Titan
Cardiol Therapeutics will join a heart-disease drug chat in New York Sept. 14 - Stock Titan
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Cardiol Therapeutics Inc (CRDL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cardiol Therapeutics Inc. (TSX:CRDL) Climbs 10.18% as Phase III Catalyst and CardiolRx Momentum Strengthen Investor Optimism - kalkine.ca
Cardiol Therapeutics (TSX:CRDL) Falls 5.92% as Clinical Trial Uncertainty and Biotech Sector Volatility Pressure Investor Sentiment - kalkine.ca
Cardiol Therapeutics Inc Class A (CRDL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cardiol Therapeutics Stock Falls 3.37%: Is TSX:CRDL Facing Biotech Volatility as Clinical and Funding Risks Persist? - kalkine.ca
Cardiol Therapeutics Inc Class A (CRDL) Peer Comparison – Compare with Others - Value Research
Cardiol Therapeutics Inc. (TSX:CRDL) Gains Momentum as Clinical Pipeline Progress and Heart Disease Therapies Drive Investor Optimism - kalkine.ca
B.Riley initiates Cardiol Therapeutics stock with buy rating on pericarditis drug potential - Investing.com Canada
Cardiol Therapeutics (TSX:CRDL) Rallies 7% as Analyst Upgrades Build on Trial Progress - kalkine.ca
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Cardiol (CRDL) Earnings Snapshot: EPS Lands Above Forecast in the Latest Reading; Share Move: The Stock Loses 1.33% at the CloseMargin Expansion Trends - vinanet.vn
Cardiol (CRDL) Close: Ends Lower by 1.33% at $1.86 in Latest Trading; Technical View: the Supplied Trading Band Runs From $1.77 to $1.95 in the Current UpdateIPO Entry Watch - vinanet.vn
Cardiol Therapeutics Stock Falls 3.33% as Investors Weigh Phase III MAVERIC Promise Against Clinical-Trial and Biotech Execution Risk - kalkine.ca
Cardiol Therapeutics Drops as Biotech Risk Appetite Fades — Could the Next Clinical Update Change Everything? - kalkine.ca
Cardiol Therapeutics Inc (CRDL) Stock Price, Trades & News - GuruFocus
Cardiol (CRDL) Quarterly Results: The Bottom-Line Figure Beats Its Comparison in the Latest Session; Price Move: The Stock Ends Down 2.04% in the Current UpdateCFO Commentary Report - vinanet.vn
Cardiol Therapeutics Stock Surges 4.82% as Phase III Progress and CardiolRx Pipeline Support Investor Optimism - kalkine.ca
Why Cardiol Therapeutics Inc Class A stock went up yesterday - Wealth Awesome
Cardiol (CRDL) Financial Results: EPS Exceeds Its Estimate in the Latest Reading; Market Move: The Stock Gains 5.28% on the DayEarnings Manipulation Risk - vinanet.vn
Cardiol Therapeutics Stock: A Pivotal Pericarditis Readout Draws Nearer - kalkine.ca
What's Going On With Cardiol Therapeutics Inc Class A Stock Tuesday? - Wealth Awesome
symbol__ Stock Quote Price and Forecast - CNN
CRDL Maintains Buy Rating by Canaccord Genuity -- Price Target R - GuruFocus
CRDL Q1 2026 Earnings: Narrower-Than-Expected Loss Underscores Pipeline Cost DisciplineShare Dilution Risk - vinanet.vn
Why Cardiol Therapeutics Inc Class A stock is gaining today - Wealth Awesome
Cardiol Therapeutics (CRDL) Advances 5.26% as Shares Test Key Resistance Near $1.89IPO Entry Watch - vinanet.vn
Canaccord Genuity Group Issues Positive Forecast for Cardiol Therapeutics (NASDAQ:CRDL) Stock Price - MarketBeat
CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Could Cardiol Therapeutics Stock Be Entering a Major Catalyst Phase as MAVERIC Enrollment Nears Completion? - kalkine.ca
Q3 EPS Estimate for Cardiol Therapeutics Raised by Analyst - MarketBeat
Wall Street Zen Upgrades Cardiol Therapeutics (NASDAQ:CRDL) to Hold - MarketBeat
MMCAP and MM Asset Management (CRDL) reveal 21.3M-share Cardiol Therapeutics stake - Stock Titan
Why Cardiol Therapeutics Inc Class A stock is sliding today - Wealth Awesome
Cardiol Therapeutics Inc Class A CRDL Earnings Beat Estimates by 50.0% - Wealth Awesome
Cardiol Therapeutics Inc. Stock Surges 5.66% as Trading Activity Spikes and Market Attention Builds - kalkine.ca
Cardiol Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cardiol Therapeutics Reports Second-Quarter 2026 Interim Results - TipRanks
Cardiol Therapeutics (NASDAQ:CRDL) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Cardiol Therapeutics (CRDL) posts Q2 2026 loss but extends cash runway to Q4 2027 - Stock Titan
Cardiol Therapeutics Inc Azioni (CRDL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.56%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):